Skip to main content


Phone (Primary):


Download CV

Education and Training


2007     Ph.D., Applied Biology, Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), University of Mumbai, Mumbai, India

2001     M.Sc., Microbiology, Dept. of Microbiology & Biotechnology, M. S. University of Baroda, India

1999     B.Sc., Biochemistry & Vocational Biotechnology, St. Xavier’s college, Gujarat University, Ahmedabad, India       


My expertise is in the field of cancer biology both at the basic and translational level.

I joined, Advanced centre for treatment and research in cancer (ACTREC) institute- University of Mumbai, in 2002. Under the guidance of Dr. K.V.K Rao, I found out the role of signalling pathways and G1/S cell cycle regulatory proteins in DEN (diethylnitrosamine) induced liver cancer in rat modal system. We identified the casual link between the upregulation of MAP kinases, Akt, PAK1 pathways and G1/S regulatory cyclin D1 protein in step wise liver cancer development that was confirmed further by in vitro experiments with chemopreventive inhibitory agent resveratrol.These work led to two of my highly cited papers along with the best oral presentation award at the annual convention of IACR, India. In extension to that I also defended my innovative project proposal on “Unravelling the mechanisms of paternal imprinting”. During my postdoctoral training at Dr. Dinah Singer’s lab at NCI, NIH; I acquired the skills for molecular biology. In her lab, I received in depthresearch experience in the field of transcriptional regulation, chromatin, immunology and characterized the novel mammalian boundary element/s of MHC class I gene.This work resulted in to my second authored publication in Plos One. To continue with my fascination for cancer biology, I joined Dr. William Bonner at NCI, NIH. Being in the lab of the discoverer of DNA damage marker-gamma H2AX; I obtained in valuable expertise in measuring drug/radiation induced DNA damage that directly measures the biological response of chemical/radiation. My main focus is on evaluating the reliability of surrogate tissues and γH2AX as a predictive marker in drug development. Here we identified the efficacy and toxicity issues of various known chemotherapeutic agents preclinically; using γH2AX kinetics and humanized multi-cellular 3D tissues. This work received the recognition by receiving the prestigious Merit award from ASCO to attend Markers in Cancer 2012 meeting. In addition to this, I have pioneered the project on mild hypothermia and cancer. This project has gained appreciation by receiving the distinguished NCI Director’s intramural innovation award 2012. Apart from these, I contributed towards the basic research about uncovering the role of other histone variants in genomic integrity. Above to all these, I collaborated for several other project within the lab as well as extramurally with other scientific groups at the FDA, USA; Peter MacCallum cancer center, Australia and CEA, iBiTec-S, France. Also, obtained valuable experience and technical skills in the field of bystander effects, oxidative stress and melanoma.

Research/Clinical Keywords

DNA damage & Repair, 3D tissue, Oxidative stress, Low-dose radiation, gammaH2AX, hnRNPA18, NADPH Oxidase, cell signaling, cell cycle

Highlighted Publications

  1. Parekh PR, Chaudhari R, et al. Establish the utility of surrogate tissue by exploiting the humanized multicellular 3D skin melanoma tissue model during drug development. Accepted in Cancer Medicine (March 2016)
  2. Chang ET, Parekh PR, et al. Rational targeting of protein translation in cancer cells. Oncotarget. 2016 Mar 1;7(9):10578-93.
  3. Nguyen DM*, Parekh PR*, et al. Contribution of Dual Oxidase 2 (DUOX2) to hyper radiosensitivity in human Gastric Cancer Cells. Radiation Research 2015 Aug;184(2):151-60.(*Equal First Authors)
  4. Weyemi U, Redon CE, Aziz T, Chaudhari R, Maeda D, Parekh PR, et al. NADPH oxidase 4 is a critical mediator in Ataxia telangiectasia disease. Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2121-6.
  1. Weyemi U, Redon CE, Choudhuri R, Aziz T, Maeda D, Boufraqech M, Parekh PR, et al. The histone variant H2A.X is a regulator of the epithelial-mesenchymal transition. Nat Commun. 2016 Feb 15;7:10711.
  1. Weyemi U, Redon CE, Aziz T, Maeda D, Parekh PR, Arbiser J, Bonner WM. Inactivation of NADPH oxidases Nox4 and Nox5 protects from ionizing radiation-induced DNA damage. Radiat Res. 2015 Mar;183(3):262-70.
  2. Parekh P, Motiwale LS, Naik N and Rao KV. Down regulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. Exp Toxicol Pathol. 2011 Jan; 63(1-2): 167-73.
  3. Parekh P, Rao KV. Over expression of cyclin D1 is associated with elevated levels of MAP kinases, Akt and Pak1 during diethylnitrosamine induced progressive liver    carcinogenesis. Cell Biol Int. 2007 Jan; 31 (1): 35-43.     

Awards and Affiliations

2012                NCI Director’s Intramural Innovation Award for Career Development, NCI, NIH, Bethesda, Maryland

2012               Merit Award from American Society of Clinical Oncology for “Markers in Cancer Meeting 2012”, Hollywood, Florida, USA

2006                Award for Best Oral Presentation at the 25th Annual Convention of the Indian Association of Cancer Research and silver jubilee symposium on Molecular Profiling and Cancer management, Navi Mumbai, India

2005-2006       Recipient of Senior Research Fellowship (PhD studies), Department of Atomic Energy (DAE), Government of India   

2002-2005       Recipient of Junior Research Fellowship (PhD studies), DAE, India           

Edit Icon - Click to update your profileUpdate Your Profile